Co-administration of Acetaminophen with Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants – The ACEDUCT Trial
This study, called ACEDUCT, is testing a new way to treat a common heart condition known as Patent Ductus Arteriosus (PDA) in extremely premature babies. PDA is when a small blood vessel near the heart doesn't close properly after birth. Doctors are investigating if giving a combination of paracetamol (like Calpol) and ibuprofen (like Nurofen) together works better than current treatments. They want to see if this combination can help reduce serious problems like babies dying before leaving the hospital, or needing a lot of oxygen support for their breathing at 36 weeks of age, which is when they would typically have been due to be born. The hope is to find a safer and more effective way to help these vulnerable babies.
At a glance
What is this study about?
This research study, called ACEDUCT, is looking into the best way to help extremely premature babies who have a condition called Patent Ductus Arteriosus (PDA). PDA is a common problem in premature babies where a blood vessel near the heart, which is open during pregnancy, doesn't close properly after birth. This can put a strain on the baby's heart and lungs.
Currently, doctors often use medications like ibuprofen to try and close this vessel. This study is exploring whether giving paracetamol (a common pain reliever like Calpol) alongside ibuprofen might be a more effective treatment. The main goal is to see if this combined treatment can help reduce the chances of these very tiny babies dying before they leave the hospital, or needing a lot of help with their breathing as they get older, specifically around the time they would have been due to be born naturally (36 weeks gestational age).
The researchers will also be looking at other important things, such as whether the PDA closes successfully, if the babies have any kidney or liver problems after the treatment, and how many babies need further treatments or surgery for their PDA. They will also track how long babies need breathing support and other health issues like infections.
Key takeaways
- The ACEDUCT study aims to improve PDA treatment in extremely premature babies.
- It tests combining paracetamol and ibuprofen for better outcomes.
- The main focus is on reducing death and improving breathing at 36 weeks gestational age.
- Additional health aspects like kidney/liver function and further PDA treatments are also monitored.
- Participation involves close monitoring within existing hospital care.
Who may be eligible?
This study is designed for extremely premature babies. The researchers will be looking for specific health details of the baby to decide if they can take part.
Every baby in the study will be carefully monitored by the doctors and nurses. The research team will review each baby’s individual health situation to see if they meet the criteria to join.
If you have a baby who might be eligible, the hospital team will provide you with all the necessary information and answer any questions you may have before any decisions are made.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Is my baby extremely premature?
- Does my baby have Patent Ductus Arteriosus (PDA)?
- Is my baby currently in the Neonatal Intensive Care Unit (NICU)?
- Are doctors discussing treatment options for my baby's PDA?
What does participation involve?
If your baby takes part in this study, they will receive treatment with either a combination of paracetamol and ibuprofen, or a dummy treatment (saline solution) given into a vein. All babies will continue to receive the standard good medical care they need. Doctors and nurses will closely monitor your baby's health, particularly their heart, lungs, kidneys, and liver, throughout the treatment period. There won't be extra hospital visits beyond what your baby already needs, as all monitoring will happen while they are in the Neonatal Intensive Care Unit (NICU). The study will track your baby's progress up until 36 weeks after conception (their 'postmenstrual age'), which means they will be followed for several weeks.
Potential risks and benefits
Locations (1)
- —UnverifiedIreland
Common questions
What is PDA?
PDA stands for Patent Ductus Arteriosus. It's a common heart condition in premature babies where a blood vessel near the heart doesn't close properly after birth, which can affect their breathing and heart function.
What medications are being tested?
The study is looking at giving a combination of paracetamol (similar to Calpol) and ibuprofen (similar to Nurofen) to see if it helps close the PDA.
What is the main goal of the study?
The main goal is to see if this combined treatment can help very premature babies survive and breathe better without needing a lot of oxygen as they grow.
Will my baby receive extra treatments if they join?
Beyond the study medication, your baby will continue to receive all the standard care needed in the Neonatal Intensive Care Unit (NICU). The study will not add extra non-invasive or invasive procedures.
Can I take my baby out of the study if I change my mind?
Yes, you can choose to withdraw your baby from the study at any time, and this will not affect the medical care they receive.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.